<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526081</url>
  </required_header>
  <id_info>
    <org_study_id>429275-10</org_study_id>
    <nct_id>NCT03526081</nct_id>
  </id_info>
  <brief_title>Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides</brief_title>
  <official_title>Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mars, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probe dietary intervention study in healthy young adult males to evaluate the concentration
      of apigenin derived metabolites in plasma and urine after single acute intakes of different
      apigenin-containing test materials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Flavonoids, including the sub groups of Flavones (FO) are plant-derived compounds commonly
      present in the human diet. Examples of FO-containing foods and beverages are parsley, celery,
      and chamomile. The study described below will provide initial information of apigenin derived
      metabolites in humans. The investigators suggest the information that will be obtained from
      the outlined work will be particularly timely given increasing interest in the putative
      health effects of FO intake in humans.

      This study consisted of two parts. The first part consisted of a probe study in which the
      investigators investigated the absorption and metabolism from four flavone-containing test
      products. The second phase investigated absorption and metabolism after the intake of a
      flavone-containing parsley drink.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Cross-over dietary intervention study in healthy young adult males</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Investigator doing data analysis and statistical analyses</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Flavone metabolites in plasma</measure>
    <time_frame>before to 6 h post test material intake</time_frame>
    <description>Concentration of flavone metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flavone metabolites in urine</measure>
    <time_frame>12 h before to 24 h post test material intake</time_frame>
    <description>Amount of flavone metabolites excreted in urine</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Chamomile Tea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chamomile Tea in 300mL hot water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parsley based drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.2 g dried parsley in 300mL hot water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parsley Yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.2 g dried parsley in 100g plain yogurt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apigenin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apigenin capsule mixed with 300mL hot water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parsley-based drink (II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.2 g of dried parsley in 300 ml of hot water</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chamomile Tea</intervention_name>
    <description>Chamomile Tea in 300mL hot water</description>
    <arm_group_label>Chamomile Tea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parsley based drink</intervention_name>
    <description>3.2 g dried parsley in 300mL hot water</description>
    <arm_group_label>Parsley based drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parsley Yogurt</intervention_name>
    <description>3.2 g dried parsley in 100g plain yogurt</description>
    <arm_group_label>Parsley Yogurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apigenin</intervention_name>
    <description>Apigenin capsule mixed with 300mL hot water</description>
    <arm_group_label>Apigenin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parsley-based drink (II)</intervention_name>
    <description>3.2 g dried parsley in 300mL hot water</description>
    <arm_group_label>Parsley-based drink (II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No prescription medications

          -  BMI 18.5 - 29.9 kg/m2

          -  Weight ≥ 110 pounds

          -  previously consumed cocoa, peanut, parsley, celery and chamomile products with no
             adverse reactions

        Exclusion Criteria:

          -  Adults unable to consent

          -  Prisoners

          -  Non-English speaking*

          -  BMI ≥ 30 kg/m2

          -  Performing vigorous physical activity (i.e. more than 6 MET; metabolic equivalence of
             task as defined by CDC and ACSM guidelines
             (http://www.cdc.gov/physicalactivity/everyone/glossary/index.html#vig-intensity; and
             http://www.cdc.gov/nccdphp/dnpa/physical/pdf/PA_Intensity_table_2_1.pdf ) for more
             than 3 days a week.

          -  Dietary allergies including those to nuts, cocoa and chocolate products, parsley,
             celery and chamomile.

          -  Active avoidance of coffee and caffeinated soft drinks

          -  Under current medical supervision

          -  A history of cardiovascular disease, stroke, renal, hepatic, or thyroid disease

          -  History of clinically significant depression, anxiety or other psychiatric condition

          -  History of Raynaud's disease

          -  History of difficult blood draws

          -  Indications of substance or alcohol abuse within the last 3 years

          -  Current use of herbal, plant or botanical supplements (multi-vitamin/mineral
             supplements are allowed)

          -  Blood Pressure &gt; 140/90 mm Hg

          -  GI tract disorders, previous GI surgery (except appendectomy)

          -  Self-reported malabsorption (e.g. difficulty digesting or absorbing nutrients from
             food, potentially leading to bloating, cramping or gas)

          -  Diarrhea within the last 3 months, or antibiotic intake within the last 3 months

          -  Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight
             loss diet or individuals following diets with significant deviations from the average
             diet

          -  Metabolic panel and cholesterol results or complete blood counts that are outside of
             the normal reference range and are considered clinically relevant by the study
             physician

          -  Cold, flu, or upper respiratory condition at screening

          -  Currently participating in a clinical or dietary intervention study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl L Keen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier I Ottaviani, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mars, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ragle Human Nutrition Research Center, Department of Nutrition at UC Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH. Recommending flavanols and procyanidins for cardiovascular health: current knowledge and future needs. Mol Aspects Med. 2010 Dec;31(6):546-57. doi: 10.1016/j.mam.2010.09.008. Epub 2010 Sep 18. Review.</citation>
    <PMID>20854838</PMID>
  </reference>
  <reference>
    <citation>Ottaviani JI, Momma TY, Kuhnle GK, Keen CL, Schroeter H. Structurally related (-)-epicatechin metabolites in humans: assessment using de novo chemically synthesized authentic standards. Free Radic Biol Med. 2012 Apr 15;52(8):1403-12. doi: 10.1016/j.freeradbiomed.2011.12.010. Epub 2011 Dec 23.</citation>
    <PMID>22240152</PMID>
  </reference>
  <reference>
    <citation>Koster H, Halsema I, Scholtens E, Knippers M, Mulder GJ. Dose-dependent shifts in the sulfation and glucuronidation of phenolic compounds in the rat in vivo and in isolated hepatocytes. The role of saturation of phenolsulfotransferase. Biochem Pharmacol. 1981 Sep 15;30(18):2569-75.</citation>
    <PMID>6946775</PMID>
  </reference>
  <reference>
    <citation>McCullough ML, Chevaux K, Jackson L, Preston M, Martinez G, Schmitz HH, Coletti C, Campos H, Hollenberg NK. Hypertension, the Kuna, and the epidemiology of flavanols. J Cardiovasc Pharmacol. 2006;47 Suppl 2:S103-9; discussion 119-21.</citation>
    <PMID>16794446</PMID>
  </reference>
  <reference>
    <citation>Heiss C, Kleinbongard P, Dejam A, Perré S, Schroeter H, Sies H, Kelm M. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol. 2005 Oct 4;46(7):1276-83.</citation>
    <PMID>16198843</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>flavone</keyword>
  <keyword>ADME</keyword>
  <keyword>apigenin</keyword>
  <keyword>parsley</keyword>
  <keyword>chamomile</keyword>
  <keyword>polyphenols</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Glycosides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Only researchers listed in the protocol and approved by the IRB will have access to IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

